AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...

AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...

Tavapadon, a drug being tested to treat early Parkinson's disease, has shown great promise in a Phase III trial by AbbVie, ...

Philip Stevens, a 66 year old from Hampshire, has received £70,000 from his GP following a lawsuit after he was given the ...

Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's ...

Why digital measurements startup Koneksa Health thinks it can help pharma measure if their drugs are effective in people with ...

Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart ...

Hello from San Diego, where I always happen to be, but where this weekend I had the delight of hanging out with coworkers ...

Two teams of scientists have recently come up with potential breakthroughs with preventing a serious side effect of Parkinson ...

Annovis Bio, Inc. operates in the biopharmaceutical industry, focusing on developing therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. Their primary product, ...

“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

Growing older is the greatest risk factor for acquiring Parkinson’s disease and many people live with symptoms for several years before being diagnosed. Often people in early stages of Parkinson’s ...